Korean Journal of Veterinary Service (한국동물위생학회지)

The Korean Society of Veterinary Service (한국동물위생학회)
권호 표지
DOI QR코드

DOI QR Code

Effectiveness of Danazol as an adjunctive therapy in dogs with immune-mediated hemolytic anemia

  • Yo, Sechul (College of Veterinary Medicine, Chungnam National University) ;
  • Park, Hyung-Jin (Sungsim Animal Medical Center) ;
  • Song, Kun-Ho (College of Veterinary Medicine, Chungnam National University)
  • Received : 2022.05.28
  • Accepted : 2022.07.27
  • Published : 2022.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Immune-mediated hemolytic anemia (IMHA) is autoimmune disease which is anemia caused by own immune system destroying the red blood cells (RBC). It can be diagnosed with spherocytosis, positive auto-agglutination of RBCs and direct antiglobulin test (DAT, Coomb's test). The treatment for IMHA are blood transfusion, immunosuppressive agents including glucocorticoids and other supportive therapies. Danazol is synthetic androgen that has effect of interfering the autoimmune reaction to RBCs. It can be used as an adjunctive agent in addition to glucocorticoids. To investigate its effectiveness, the medical records of 10 IMHA-diagnosed dogs were evaluated. All subjects were treated with blood transfusion, prednisolone, mycophenolate mofetil, and intravenous human immunoglobulin G. Additionally, 6 subjects were administered with danazol and 4 subjects were not. The results of initial blood examination and responses to the treatment for IMHA were compared between the groups. There were significant differences in the number of blood transfusions; once in group with danazol, twice in group without danazol, duration of recovery to normal hematocrit; 7.67±3.08 days in group with danazol, 22.00±5.66 days in group without danazol, and hospitalization; 5.17±0.75 days in group with danazol, 12.75±2.22 days in group without danazol. Therefore, danazol has potential effective on treating IMHA for rapid improvement.

Keywords

Acknowledgement

Samples of this work were provided by Sungsim Animal Medical Center.

References

  1. Balch A, Mackin A. 2007. Canine immune-mediated hemolytic anemia: pathophysiology, clinical signs, and diagnosis. Compendium (Yardley, PA). 29: 217-225.
  2. Balch A, Mackin A. 2007. Canine immune-mediated hemolytic anemia: treatment and prognosis. Compendium (Yardley, PA). 29: 230-238.
  3. Bloom JC, Meunier LD, Thiem PA, Sellers TS. 1989. Use of danazol for treatment of corticosteroid-resistant immune-mediated thrombocytopenia in a dog. J Am Vet Med Assoc 194: 76-78.
  4. Chai KY, Quijano CJ, Chiruka S. 2019. Danazol: an effective and underutilized treatment option in diamond-blackfan anaemia. Case Rep Hematol 2019: article ID 4684156.
  5. Garden OA, Kidd L, Mexas AM, Chang YM, Jeffery U, Blois SL, Fogle JE, MacNeill AL, Lubas G, Birkenheuer A, Buoncompagni S, Dandrieux JRS, Di Loria A, Fellman CL, Glanemann B, Goggs R, Granick JL, LeVine DN, Sharp CR, Smith-Carr S, Swann JW, Szladovits B. 2019. ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. J Vet Intern Med 33: 313-334. https://doi.org/10.1111/jvim.15441
  6. Goggs R. 2020. Therapeutic strategies for treatment of immune-mediated hemolytic anemia. Vet Clin Small Anim 50: 1327-1349. https://doi.org/10.1016/j.cvsm.2020.07.010
  7. Grundy SA, Barton C. 2001. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). J Am Med Assoc 218: 543-546. https://doi.org/10.2460/javma.2001.218.543
  8. Holloway SA, Meyer DJ. 1990. Prednisolone and danazol for treatment of immune-mediated anemia, thrombocytopenia, and ineffective erythroid regeneration in a dog. J Am Vet Med Assoc 197: 1045-1048.
  9. McCullough S. 2003. Immune-mediated hemolytic anemia: understanding the nemesis. Vet Clin Small Anim 33: 1295-1315. https://doi.org/10.1016/j.cvsm.2003.08.003
  10. Miller E. 1997. Danazol therapy for the treatment of immune-mediated hemolytic anemia in dogs (abstr). J Vet Intern Med 11: 130.
  11. Piek CJ, Junius G, Dekker A, Schrauwen E, Slappendel RJ, Teske E. 2008. Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs. J Vet Intern Med 22: 366-373. https://doi.org/10.1111/j.1939-1676.2008.0060.x
  12. Reimer ME, Troy GC, Warnick LD. 1999. Immunemediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 35: 384-391. https://doi.org/10.5326/15473317-35-5-384
  13. Swann JW, Garden OA, Fellman CL, Glanemann B, Goggs R, LeVine DN, Mackin AJ, Whitely NT. 2019. ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs. J Vet Intern Med 33: 1141-1172. https://doi.org/10.1111/jvim.15463
  14. Swann JW, Skelly BJ. 2013. Systematic review of evidence relating to the treatment of immune-mediated hemolytic anemia in dogs. J Vet Intern Med 27: 1-9. https://doi.org/10.1111/jvim.12028
  15. Whitley NT, Day MJ. 2011. Immunomodulatory drugs and their application to the management of canine immune-mediated disease. J Small Anim Pract 52: 70-85 https://doi.org/10.1111/j.1748-5827.2011.01024.x